Identification of prognostic and bone metastatic alternative splicing signatures in bladder cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Wang Ning LS, Lei Y, Xi Z, et al. Interpretation on the report of Global Cancer Statistics 2018. J Multidiscip Cancer Manage. 2019;Electronic version:01–10.
   Google Scholar
• von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gonzalez-Porta M, Santos S, et al. Impact of Alternative Splicing on the Human Proteome. Cell Rep. 2017;20:1229–1241.
   PubMed Web of Science ®Google Scholar
• Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–1415.
   PubMed Web of Science ®Google Scholar
• Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470–476.
   PubMed Web of Science ®Google Scholar
• Climente-Gonzalez H, Porta-Pardo E, Godzik A, et al. The Functional Impact of Alternative Splicing in Cancer. Cell Rep. 2017;20:2215–2226.
   PubMed Web of Science ®Google Scholar
• Aversa R, Sorrentino A, Esposito R, et al. Alternative splicing in adhesion- and Motility-related genes in Breast Cancer. Int J Mol Sci. 2016;17:121.
   Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.
   PubMed Web of Science ®Google Scholar
• He RQ, Zhou XG, Yi QY, et al. Prognostic signature of alternative splicing events in bladder urothelial carcinoma based on spliceseq data from 317 cases. Cell Physiol Biochem. 2018;48:1355–1368.
   PubMedGoogle Scholar
• Marzese DM, Manughian-Peter AO, Orozco JIJ, et al. Alternative splicing and cancer metastasis: prognostic and therapeutic applications. Clin Exp Metastasis. 2018;35:393–402.
   PubMed Web of Science ®Google Scholar
• Ryan M, Wong WC, Brown R, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 2016;44:D1018–1022.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297–303.
   PubMed Web of Science ®Google Scholar
• Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385–395.
   PubMed Web of Science ®Google Scholar
• Piva F, Giulietti M, Nocchi L, et al. SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans. Bioinformatics. 2009;25:1211–1213.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–658.
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956–d963.
   PubMed Web of Science ®Google Scholar
• Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013;8:e74250.
   PubMed Web of Science ®Google Scholar
• Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the Cancer cell line encyclopedia. Nature. 2019;569:503–508.
   PubMed Web of Science ®Google Scholar
• Thul PJ, Åkesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321.
   Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–w102.
   PubMed Web of Science ®Google Scholar
• Hafemeister C, Satija R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 2019;20:296.
   PubMed Web of Science ®Google Scholar
• Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20:163–172.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lan Y, Xu J, et al. CellMarker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 2019;47:D721–d728.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
   PubMed Web of Science ®Google Scholar
• Wickman H. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
   Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
   PubMed Web of Science ®Google Scholar
• Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–193.
   PubMed Web of Science ®Google Scholar
• Baras AS, Drake C, Liu JJ, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5:e1134412.
   PubMed Web of Science ®Google Scholar
• Le KQ, Prabhakar BS, Hong WJ, et al. Alternative splicing as a biomarker and potential target for drug discovery. Acta Pharmacol Sin. 2015;36:1212–1218.
   PubMed Web of Science ®Google Scholar
• Fang J, Xiao L, Zhang Q, et al. Junction plakoglobin, a potential prognostic marker of oral squamous cell carcinoma, promotes proliferation, migration and invasion. J Oral Pathol Med. 2019;49(1):30–38.
   Web of Science ®Google Scholar
• Lewalle JM, Bajou K, Desreux J, et al. Alteration of interendothelial adherens junctions following tumor cell-endothelial cell interaction in vitro. Exp Cell Res. 1997;237:347–356.
   PubMed Web of Science ®Google Scholar
• Cowin P, Kapprell HP, Franke WW, et al. Plakoglobin: a protein common to different kinds of intercellular adhering junctions. Cell. 1986;46::1063–1073.
   PubMed Web of Science ®Google Scholar
• Holen I, Whitworth J, Nutter F, et al. Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res. 2012;14:R86.
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Harrington K, Waxman J, et al. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol. 1998;160:1889–1893.
   PubMed Web of Science ®Google Scholar
• Rieger-Christ KM, Ng L, Hanley RS, et al. Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer. 2005;92:2153–2159.
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.
   PubMed Web of Science ®Google Scholar
• Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816–826.
   PubMed Web of Science ®Google Scholar
• Liu SY, Ge D, Chen LN, et al. A small molecule induces integrin beta4 nuclear translocation and apoptosis selectively in cancer cells with high expression of integrin beta4. Oncotarget. 2016;7:16282–16296.
   PubMedGoogle Scholar
• Giancotti FG. Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci. 2007;28:506–511.
   PubMed Web of Science ®Google Scholar
• Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol. 2003;19:173–206.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687.
   PubMed Web of Science ®Google Scholar
• Kettunen E, Nicholson AG, Nagy B, et al. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis. 2005;26::17–25.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Jiang H, Qu Y, et al. Metallopanstimulin-1 regulates invasion and migration of gastric cancer cells partially through integrin beta4. Carcinogenesis. 2013;34:2851–2860.
   PubMed Web of Science ®Google Scholar
• Leng C, Zhang ZG, Chen WX, et al. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. Cancer Lett. 2016;376:188–196.
   PubMed Web of Science ®Google Scholar
• Ferraro A, Kontos CK, Boni T, et al. Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGBeta4-PDCD4) as predictor of metastatic tumor potential. Epigenetics. 2014;9:129–141.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Lee C, Bromberg J, et al. Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer. Oncol Rep. 2000;7::13–16.
   PubMed Web of Science ®Google Scholar
• Brendle A, Lei H, Brandt A, et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis. 2008;29:1394–1399.
   PubMed Web of Science ®Google Scholar
• Chen Q, Xu R, Zeng C, et al. Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin beta4-mediated FAK signaling. PLoS One. 2014;9:e88386.
   PubMed Web of Science ®Google Scholar
• Kashyap T, Germain E, Roche M, et al. Role of beta4 integrin phosphorylation in human invasive squamous cell carcinoma: regulation of hemidesmosome stability modulates cell migration. Lab Invest. 2011;91:1414–1426.
   PubMed Web of Science ®Google Scholar
• Gagnoux-Palacios L, Dans M. van’t Hof W, et al. Giancotti FG: compartmentalization of integrin alpha6beta4 signaling in lipid rafts. J Cell Biol. 2003;162:1189–1196.
   PubMed Web of Science ®Google Scholar
• Stewart RL, O’Connor KL. Clinical significance of the integrin alpha6beta4 in human malignancies. Lab Invest. 2015;95:976–986.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Rabinovitz I, Wang HH, et al. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell. 1997;91:949–960.
   PubMed Web of Science ®Google Scholar
• Li XL, Liu L, Li DD, et al. Integrin beta4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Sci Rep. 2017;45:40464.
   Google Scholar
• Kawamura S, Ohyama C, Watanabe R, et al. Glycolipid composition in bladder tumor: a crucial role of GM3 ganglioside in tumor invasion. Int J Cancer. 2001;94:343–347.
   PubMed Web of Science ®Google Scholar
• Hakomori S. Structure, organization, and function of glycosphingolipids in membrane. Curr Opin Hematol. 2003;10:16–24.
   PubMed Web of Science ®Google Scholar
• Wang H, Isaji T, Satoh M, et al. Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model. Urology. 2013;81:210. [ e211-215].
   Web of Science ®Google Scholar
• Hakomori SI, Handa K. GM3 and cancer. Glycoconj J. 2015;32:1–8.
   PubMed Web of Science ®Google Scholar
• Satoh M, Ito A, Nojiri H, et al. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int J Oncol. 2001;19::723–731.
   PubMed Web of Science ®Google Scholar